RxDoctor Payments Data

Srujitha Murukutla, MD

Internal Medicine · Rehoboth Beach, DENPI 1578792966

Payments from drug & device makers

$1,325in general payments, 2019–2025

Across 51 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$188
  • GSK$162
  • Regeneron Healthcare Solutions, Inc.$158
  • AstraZeneca$141
  • Lilly USA, LLC$116
  • Johnson & Johnson$97
  • plus $464 from 22 others

What the payments were for

  • Food & beverage$1,29698%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,325 in reported general payments places this provider in the 80th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$137,396
Medicare patients
595
Services billed
1,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$14,806
Anastrozole154$3,844
Tamoxifen Citrate35$1,430
Exemestane19$1,420
Letrozole52$1,194
Lidocaine-PrilocaineLidocaine/Prilocaine62$698
Prochlorperazine Maleate68$537
Ondansetron Hcl64$462
Dexamethasone40$306
Hydroxyurea22$210
Gabapentin22$138
Prednisone27$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$14,80616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Rehoboth Beach

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →